Status Examination is in progress Database last updated on 06.12.2013 Most recent event Tooltip 29.10.2013 New entry: Application deemed to be withdrawn: despatch of communication + time limit Applicant(s) For all designated states AMDL, Inc. 2492 Walnut Avenue, Suite 100 Tustin, CA 92780-6953 / US [2012/06] Inventor(s) 01 / SMALL-HOWARD, Andrea 12403 Jersey Avenue Norwalk CA 90650 / US [2012/06] Representative(s) Potter Clarkson LLP The Belgrave Centre, Talbot Street, Nottingham NG1 5GG / GB [2013/37] Former [2012/06] Wright, Andrew John Potter Clarkson LLP Park View House 58 The Ropewalk Nottingham NG1 5DD / GB Application number, filing date 09789550.2 30.03.2009 WO2009US38833 Priority number, date deleted [2012/06] Filing language EN Procedural language EN Publication Type : A1 Application with search report No. : WO2010114514 Date : 07.10.2010 Language : EN [2010/40] Type : A1 Application with search report No. : EP2414843 Date : 08.02.2012 Language : EN The application has been published by WIPO in one of the EPO official languages on 07.10.2010 [2012/06] International and Supplementary search report(s) International search report - published on: EP 07.10.2010 Classification International : G01N33/574, G01N33/86 [2012/06] Designated contracting states AT , BE , BG , CH , CY , CZ , DE , DK , EE , ES , FI , FR , GB , GR , HR , HU , IE , IS , IT , LI , LT , LU , LV , MC , MK , MT , NL , NO , PL , PT , RO , SE , SI , SK , TR [2012/06] Title German : NACHWEIS VON FIBRIN- UND FIBRINOGEN-ABBAUPRODUKTEN SOWIE DAMIT VERBUNDENE VERFAHREN ZUR HERSTELLUNG UND VERWENDUNG ZUM NACHWEIS UND ZUR ÜBERWACHUNG EINER KREBSERKRANKUNG [2012/06] English : DETECTION OF FIBRIN AND FIBRINOGEN DEGRADATION PRODUCTS AND ASSOCIATED METHODS OF PRODUCTION AND USE FOR THE DETECTION AND MONITORING OF CANCER [2012/06] French : DÉTECTION DE PRODUITS DE DÉGRADATION DE FIBRINE ET DE FIBRINOGÈNE, ET PROCÉDÉS CONNEXES DE PRODUCTION ET D'UTILISATION POUR LA DÉTECTION ET LA SURVEILLANCE D'UN CANCER [2012/06] Entry into regional phase 18.10.2011 National basic fee paid 18.10.2011 Designation fee(s) paid 18.10.2011 Examination fee paid Examination procedure 18.10.2011 Examination requested [2012/06] 18.05.2012 Amendment by applicant (claims and/or description) 10.09.2013 Despatch of a communication from the examining division (Time limit: M04) 30.10.2013 Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time Divisional application(s) The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 10.09.2013 Fees paid Renewal fee 30.09.2011 Renewal fee patent year 03 26.03.2012 Renewal fee patent year 04 Penalty fee Additional fee for renewal fee 31.03.2013 05 M06 Not yet paid Cited in International search [I] US2004033544 [Y] WO9855872 [I] Anonymous: "GenWay Biotech/AMDL-ELISA DR-70 (FDP) test" online Internet article 2007, pages 1-4, XP002556535 Retrieved from the Internet: URL:http://www.genwaybio.com/images/gw_tds/elisa_kits/40-008-355001.pdf> [retrieved on 2009-11-19] [X] LI X. ET AL.: "Serum concentration of AMDL DR-70 for the diagnosis and prognosis of carcinoma of the tongue" BR. J. ORAL & MAXILLOFAC. SURG., vol. 43, no. 6, December 2005 (2005-12), pages 513-515, XP002556536
DOI: http://dx.doi.org/10.1016/j.bjoms.2004.11.020 [X] KERBER A. ET AL.: "The new DR-70 immunoassay detects cancer of the gastrointestinal tract: a validation study" ALIMEN. PHARMACOL. & THER., vol. 20, no. 9, 1 November 2004 (2004-11-01), pages 983-987, XP002556537
DOI: http://dx.doi.org/10.1111/j.1365-2036.2004.02212.x [X] WU D.F. ET AL.: "Sensitivity and specificity of DR-70(TM) lung cancer immunoassay" ANALYTICAL LETTERS, vol. 32, no. 7, May 1999 (1999-05), pages 1351-1362, XP009126042
DOI: http://dx.doi.org/10.1080/00032719908542902 [X] WU D. ET AL.: "Clinical performance of the AMDL DR-70 immunoassay kit for cancer detection" J. IMMUNOASSAY, vol. 19, no. 1, February 1998 (1998-02), pages 63-72, XP009126130 [X] RUCKER P. ET AL.: "Elevated fibrinogen-fibrin degradation products (FDP) in serum of colorectal cancer patients" ANALYTICAL LETTERS, vol. 37, no. 14, November 2004 (2004-11), pages 2965-2976, XP009126041
DOI: http://dx.doi.org/10.1081/AL-200035849 [Y] MCCABE R.P. ET AL.: "A diagnostic-prognostic test for bladder cancer using a monoclonal antibody-based enzyme-linked immunoassay for detection of urinary fibrin(ogen) degradation products" CANCER RES., vol. 44, no. 12 Part 1, December 1984 (1984-12), pages 5886-5893, XP009126033 [A] BICK R.L.: "The clinical significance of fibrinogen degradation products" SEMINARS IN THROMBOSIS AND HEMOSTASIS, vol. 8, no. 4, October 1982 (1982-10), pages 302-330, XP009126076
But that is the European patent app, not the WIPO.
Not that it matters -- DR-70 is not going to be profitable anywhere, ever, IMO. But if the WIPO app expires or is rejected, UNI won't have to pay Radient anything.